Tempest Therapeutics (TPST) Preferred Stock Liabilities (2011 - 2020)
Tempest Therapeutics (TPST) posted Preferred Stock Liabilities of $86.7 million for Q4 2020, little changed sequentially from $86.7 million in Q3 2020.
Tempest Therapeutics (TPST) Preferred Stock Liabilities (2011 - 2020) Analysis & Trends
Tempest Therapeutics has reported Preferred Stock Liabilities for 4 years, with the latest figure at $86.7 million in Q4 2020.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $86.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $86.7 million (changed N/A YoY) and the FY2020 annual result came in at $86.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $86.7 million in Q4 2020 per TPST's latest filing, from $86.7 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $86.7 million in Q3 2020 and troughed at $139000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 86.71 Mn |
| Sep 30, 2020 | 86.71 Mn |
| Dec 31, 2017 | 139,000.00 |
| Jun 30, 2012 | 34.99 Mn |
| Dec 31, 2011 | 6.20 Mn |